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Background: Adult patients with haemophilia are fre-
quently coinfected with HIV and HCV, usually due to blood
and plasma factor transfusion prior to effective screening
programs. The current standard therapy for HCV is pegy-
lated interferon and ribavirin (PEG+RBV), which has been
investigated in HCVmonoinfection and HIV/HCV coinfection.
Little data exists regarding the effectiveness of HCV ther-
apy in coinfected patients with haemophilia. We reviewed
HCV treatment outcomes in our cohort of patients with
haemophilia and HIV/HCV coinfection.
Methods: We performed a retrospective review of
all patients with haemophilia and HIV/HCV co-infection
treated with PEG+RBV at the Alfred Hospital between
2001—2007 (n = 13). Patient histories and medical records
were reviewed for demographics, adverse events and effec-
tiveness, including early, end of treatment and sustained
virological response (EVR, EOTR and SVR, deﬁned as unde-
tectable HCV viral load/PCR at 12, 48 and 72 weeks
respectively) of HCV
Results: All patients were male with haemophilia A, and
a median age of 43 (range 27—62) at initiation of HCV ther-
apy. Nine of thirteen (69%) patients had genotype (gt1) 1
HCV (gt3 = 3, gt4 = 1). Due to bleeding tendencies, only 1/13
patients underwent liver biopsy prior to HCV therapy. Twelve
of 13 (92%) were receiving ART, with a mean CD4 count of
428 cells/uL (range 175—928 cells/L) at initiation of HCV
therapy. Six of 11 (55%) patients achieved EVR (3× gt1,
2× gt3) at 12 weeks, 4/13 (31%) had EOTR (2× gt1, 2× gt3)
and 1/13 (8%) achieved SVR (gt1). 7/11 (64%) patients nor-
malised ALT during therapy wherein mean ALT fell from 101
to 76U/L. Only 1/13 (8%) patients prematurely stopped ther-
apy prematurely due to side effects. CD4 cell counts and
HIV viral load remained stable during HCV treatment, with
a mean 437 cells/uL and <50 copies/mL at 48 weeks, respec-
tively
Conclusions: Treatment responses in patients with
haemophilia and HIV/HCV coinfection were signiﬁcantly
lower from that reported in other coinfected populations.
This is despite a low drop out rate and suggests that
haemophilia is an independent risk factor for poor treatment
response. Risk factors in this cohort for poor response may
include long duration of coinfection, advanced liver disease
and unfavourable genotype proﬁle. Prospective studies in
this patient population are needed to further evaluate HCV
treatment efﬁcacy.
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Introduction: Hepatitis C virus (HCV) is a major cause
of cirrhosis and need for liver transplant. With common
risk factors for acquisition, HIV co-infection is common, and
leads to faster progression of liver ﬁbrosis. We have previ-
ously reported that combination therapy for HCV can result
in comparable sustained virological response (SVR) rates for
co-infected patients when compared to Hep C monoinfected
patients. Monitoring viral kinetics, speciﬁcally baseline HCV
viral load and week 4 HCV PCR (rapid virological response
(RVR)) can allow tailoring of treatment duration for speciﬁc
patients and give prognostic information regarding likeli-
hood of primary treatment success.
Methods: Data for 80 HIV-HCV co-infected patients
treated with pegylated-interferon and ribavirin between
2001 and 2007 was collected. Genotype 2/3 infected
patients were treated for 24 weeks only with weight-based
ribavirin. Baseline characteristics and viral kinetics were
analysed using Excel and Epi info
Results: 80 co-infected patients were treated, 84% male.
45% patients had Genotype 1 disease. Overall SVR rate was
53% using an intention-to-treat (ITT) analysis. Baseline HCV
viral load was noted to be lower in those who achieved a
SVR (6× 106 iu vs 13× 106 iu) (p < 0.05). In ITT analysis 33%
achieved a RVR response. These patients were signiﬁcantly
more likely to have a SVR than those without a RVR (96%
vs 29%) (p < 0.05). Using an on-treatment analysis 100% of
patients achieving RVR achieved SVR. Predictors of achiev-
ing RVR were HCV viral load at baseline (p < 0.05) and HCV
genotype (p < 0.05).
Conclusion: Monitoring of early viral kinetics can be used
to accurately predict those patients who will achieve SVR,
especially those for whom only 24 weeks of therapy is
required.
doi:10.1016/j.ijid.2008.05.1349
